home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

242 rows where filing_period = "second_quarter", filing_year = 2017 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 242 ✖

filing_year 1

  • 2017 · 242 ✖

filing_period 1

  • second_quarter · 242 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1982474 MR. BRIAN KELLY 3055e158-1468-402f-adf1-3fce81115852 Q2 MR. BRIAN KELLY 40024191 LUNDBECK PHARMACEUTICALS 2017 second_quarter PHA CNS Brain Disorders Alzheimer's HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2017-06-30T10:55:16.673000-04:00
1982947 WELLINGTON STRATEGIES, LLC. 1b903b62-5c13-4521-b7fb-9af47ef27b58 Q2 WELLINGTON STRATEGIES, LLC. 401104410 OMNICELL, INC. 2017 second_quarter PHA Regulations pertaining to the Drug Quality and Security Act (Public Law No: 113-54) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 15000   0 0 2017-07-05T10:01:32.560000-04:00
1983215 AMERICAN AMBULANCE ASSOCIATION c912fff0-ad65-41a4-a27b-30e879858069 Q2 AMERICAN AMBULANCE ASSOCIATION 56018 AMERICAN AMBULANCE ASSOCIATION 2017 second_quarter PHA Lobbied for passage of Protecting Patient Access to Emergency Medication Act (H.R. 304, S. 916). Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   280000 0 0 2017-07-05T17:00:49.500000-04:00
1983388 AMERICAN COLLEGE OF CLINICAL PHARMACY 55f83551-dc10-499b-87c1-0eb70db2ca35 Q2 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2017 second_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   128375 0 0 2017-07-06T12:18:21.283000-04:00
1983547 INDEPENDENT PHARMACY COOPERATIVE ff0bc16d-bc60-4eb9-84aa-ca96dced8007 Q2 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2017 second_quarter PHA Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support Affordable Care Act of 2010 Average Manufacturer Price methodology. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2017-07-06T15:35:00.467000-04:00
1983548 STANTON PARK GROUP 6f1b8a3c-3ee9-4848-9fd2-89eebac44271 2T STANTON PARK GROUP 83717 OSH'S NOT FOR PROFIT PHARMACEUTICALS 2017 second_quarter PHA information gathering regarding pharmaceutical compounding Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 1 2017-07-06T15:36:01.903000-04:00
1983674 AMERICAN CAPITOL GROUP 19103d00-b163-411a-ad14-5076c79ec73a Q2 AMERICAN CAPITOL GROUP 305852 CARDINAL HEALTH 2017 second_quarter PHA Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; HOUSE OF REPRESENTATIVES,SENATE 25000   0 0 2017-07-06T17:09:11.363000-04:00
1983682 AMERICAN CAPITOL GROUP eabaa3a7-f07d-4638-90b2-36423cf89163 2A AMERICAN CAPITOL GROUP 305852 CARDINAL HEALTH 2017 second_quarter PHA Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 25000   0 0 2017-07-06T17:16:17.237000-04:00
1983848 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 9f4a8bef-4022-4d2f-9ac2-f9a636f88622 Q2 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 401103437 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2017 second_quarter PHA Determining the intended use of drugs and/or devices and using scientific exchange to share data on "Off-label use" (HR 1703/Medical Products Communications Act of 2017) Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE     0 0 2017-07-07T11:45:34.467000-04:00
1984096 PENN AVENUE PARTNERS 1a10336a-f323-4117-a63b-6c7b82af5aee Q2 PENN AVENUE PARTNERS 400918672 PURDUE PHARMA L.P. 2017 second_quarter PHA Monitoring legislative and regulatory activities impacting the pharmaceutical industry. SENATE 60000   0 0 2017-07-07T17:50:48.440000-04:00
1984452 RED+BLUE STRATEGIES 28655048-411c-421a-9cbd-0faba9398dd3 Q2 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2017 second_quarter PHA S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-07-10T13:37:04.490000-04:00
1984497 RED+BLUE STRATEGIES d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6 Q2 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2017 second_quarter PHA S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. Issues related to the price of prescription medications in the United States. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 60000   0 0 2017-07-10T14:04:59.903000-04:00
1984555 RED+BLUE STRATEGIES fac8943f-589a-4fb2-b2cf-f3e2c2750568 Q2 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2017 second_quarter PHA S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement. Issues related opioid abuse and methods to fight against the opioid epidemic in the United States. Issues related to ensuring the safety of compounded medications. Issues related to over the counter medications and supplements. Issues related to the Physician Payment Sunshine Act and the Open Payments system. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-07-10T14:44:54.160000-04:00
1984603 WAXMAN STRATEGIES 516364b9-a563-41bd-9cbb-4ed84ba1923b Q2 WAXMAN STRATEGIES 401103693 340B HEALTH 2017 second_quarter PHA Issues affecting the 340B drug pricing program HOUSE OF REPRESENTATIVES 18750   0 0 2017-07-10T15:06:35.687000-04:00
1984730 MCDERMOTT+ LLC ba828b8b-c3bf-4a76-b728-7cf992e9b8b7 Q2 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2017 second_quarter PHA Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-07-10T17:02:56.340000-04:00
1985239 PD FRAZER CONSULTING, INC. 722bc2a8-684b-4438-9c67-7d2d5cf6122c Q2 PD FRAZER CONSULTING, INC. 65998 CANADA INTERNATIONAL PHARMACY ASSOCIATION 2017 second_quarter PHA Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2017-07-11T15:33:51.513000-04:00
1985756 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE eb355345-7deb-409b-9383-f8565185f57a Q2 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2017 second_quarter PHA Oppose S. 637 HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2017-07-12T12:46:36.527000-04:00
1986313 RUBIN AND RUDMAN LLP f50d68f0-83bc-45de-8602-167dcb834893 Q2 RUBIN AND RUDMAN LLP 400942719 BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) 2017 second_quarter PHA Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, with respect to market based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-07-13T10:32:21.423000-04:00
1986601 RED+BLUE STRATEGIES f9557be6-ef58-4ba9-a51e-0b37f2cbf16e Q2 RED+BLUE STRATEGIES 400693064 BLUE CROSS BLUE SHIELD OF MASSACHUSETTS 2017 second_quarter PHA Issues related to curbing the abuse of opioids in the United States. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-07-13T12:32:19.080000-04:00
1986622 RED+BLUE STRATEGIES 7830c1a3-b481-425a-ba64-4874b49489e9 Q2 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2017 second_quarter PHA S. 771 - A bill to improve access to affordable prescription drugs - issues related to ensuring a healthy market for biosimilar medications. S.934 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications. H.R. 2797 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications. Issues related to the treatment of biosimilar medications in Medicare Part B and D programs. Issues related to the maintenance of current IPR laws. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 60000   0 0 2017-07-13T13:01:35.477000-04:00
1986690 KATE MOSS f2027c0a-1de3-4650-a6d2-f915d135bb07 Q2 KATE MOSS 25988 CVS HEALTH 2017 second_quarter PHA Legislation impacting PBMs and drug pricing HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2017-07-13T14:10:41.623000-04:00
1986744 PARRY, ROMANI, DECONCINI & SYMMS ae5411c5-82a2-4423-9f84-da90bfaac33b Q2 PARRY, ROMANI, DECONCINI & SYMMS 30792 ROCK & ASSOCIATES 2017 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 12000   0 0 2017-07-13T14:49:19.330000-04:00
1986780 NELSON MULLINS RILEY & SCARBOROUGH b287a294-f7dd-4ccd-a766-a6820adf8cda Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 CASCADE HEMOPHILIA CONSORTIUM 2017 second_quarter PHA Issues related to 340B Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2017-07-13T15:07:48.780000-04:00
1986789 NELSON MULLINS RILEY & SCARBOROUGH 2148bf11-3e21-4bff-b2dd-7a7272ee9cba Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2017 second_quarter PHA Issues related to the 340B Drug Pricing Program and the proposed American Health Care Act HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2017-07-13T15:08:54.140000-04:00
1987935 HOLLAND & KNIGHT LLP 26d88045-a41a-42d0-b6b2-801894062fdf Q2 HOLLAND & KNIGHT LLP 18466 THE BIOSIMILARS FORUM 2017 second_quarter PHA Medicare reimbursement issues, FDA regulation of biosimilars; S. 934, H.R. 2430, the FDA Reauthorization Act of 2017. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2017-07-14T15:53:47.137000-04:00
1988011 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 08a06000-9871-4030-8644-00e6db970845 Q2 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 INOVIO PHARMACEUTICALS 2017 second_quarter PHA Government Relations Services including developing strategies to achieve legislative goals HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-07-14T16:57:55.560000-04:00
1988111 ROCK & ASSOCIATES 683a2686-d2ac-471c-ad6f-321cd72f36bf Q2 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2017 second_quarter PHA Issues pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-07-15T11:05:36.160000-04:00
1988115 ROCK & ASSOCIATES 3256e429-ce0d-4246-9b64-204ca197d884 Q2 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2017 second_quarter PHA Legislation pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-07-15T11:07:38.350000-04:00
1988117 ROCK & ASSOCIATES 9c310cd0-d52b-4fa0-96f1-bd60a847a632 Q2 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2017 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-07-15T11:09:40.273000-04:00
1988121 ROCK & ASSOCIATES 13e638d3-0657-4270-9d50-f49d977f84c7 Q2 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2017 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-07-15T11:11:42.307000-04:00
1988124 ROCK & ASSOCIATES 37443b5d-7728-47df-857b-af71348d9cd4 Q2 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2017 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-07-15T11:12:43.823000-04:00
1988127 ROCK & ASSOCIATES db4f9046-4456-4e2f-b990-5dff779fa1af Q2 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2017 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-07-15T11:13:47.837000-04:00
1988221 THE D MAJOR GROUP dc2dbf8e-fa53-4676-ba93-811c01f69e26 Q2 THE D MAJOR GROUP 401103162 CVS CAREMARK 2017 second_quarter PHA Advocate for the protection of pharmaceutical benefit management and resulting cost savings. HOUSE OF REPRESENTATIVES,SENATE 34500   0 0 2017-07-16T00:18:42.963000-04:00
1988337 BROYDRICK & ASSOCIATES fe4331e7-aa07-4397-97c4-355bfbab5975 Q2 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2017 second_quarter PHA Funding for a new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-07-16T20:11:08.307000-04:00
1988738 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 825e21dc-0760-4fcb-b7ce-5eab84c35bec Q2 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31348 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2017 second_quarter PHA Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE   763533 0 0 2017-07-17T11:01:45.610000-04:00
1988833 NOVO NORDISK INC. bd4f9eee-3900-4f08-b3e4-24d54addeac4 Q2 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2017 second_quarter PHA Issues related to H.R. 2430/S. 934 FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; issues related to 340B program Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE   830000 0 0 2017-07-17T11:30:45.490000-04:00
1988855 AMERICAN VETERINARY MEDICAL ASSOCIATION 3539675f-dcc7-4d3d-a4e8-ff11f0391368 Q2 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2017 second_quarter PHA H.R. 623, Fairness to Pet Owners Act Veterinary Compounding Draft Legislation Discussions with Congressional staff and FDA to express the need for compounding of medications for use in animals and FDA's draft GFI #230 Discussions with DEA regarding use of controlled substances by veterinary practitioners, transportation of controlled substances, telemedicine and prescription monitoring programs. Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE   200000 0 0 2017-07-17T11:31:50.880000-04:00
1988964 SQUIRE PATTON BOGGS 2f914476-aead-44f7-a524-1f8e8e28a152 Q2 SQUIRE PATTON BOGGS 30906 BIOTECHNOLOGY INNOVATION ORGANIZATION 2017 second_quarter PHA Monitoring legislation that could impact pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2017-07-17T11:56:02.807000-04:00
1989061 BUCHANAN INGERSOLL & ROONEY PC 22a2a737-9278-478c-8e56-f3d5af8591af Q2 BUCHANAN INGERSOLL & ROONEY PC 55291 60 DEGREES PHARMACEUTICALS 2017 second_quarter PHA Government relations services relating to priority review voucher within the user fee reauthorization legislation. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-07-17T12:28:23.137000-04:00
1989151 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 99461f34-0edf-49ff-bb35-8bb4cbbd0703 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2017 second_quarter PHA HR 1409, Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2017-07-17T13:07:24.303000-04:00
1989156 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 81917821-edd5-45e4-9813-9b04e81e8a8a Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2017 second_quarter PHA Issues related to the 340B drug discount program Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-07-17T13:09:25.990000-04:00
1989162 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. f330ee14-120f-4f0c-80dd-907a2abf7929 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2017 second_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2017-07-17T13:10:29.507000-04:00
1989171 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 608b3b91-7921-416a-bfad-dc09258a4834 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2017 second_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2017-07-17T13:11:30.647000-04:00
1989282 SAFEWAY INC. c94ba27c-4424-40c3-a306-448f97f9fdf4 Q2 SAFEWAY INC. 300173 SAFEWAY 2017 second_quarter PHA H.R. 592, S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions. H.R. 1038/S. 413 - Improving Transparency and Accuracy in Medicare Part D Spending Act, all provisions. H.R. 2430 - FDA Reauthorization Act of 2017, amendments related to importation of prescription drugs Implementation of 2017 NDAA Tricare Pilot. HOUSE OF REPRESENTATIVES,SENATE   80000 0 0 2017-07-17T13:51:32.467000-04:00
1989360 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 58626d71-5430-4907-ac76-1317ed8a34e4 Q2 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2017 second_quarter PHA Proposals relating to the regulation of direct-to-consumer prescription drug advertising Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Treasury, Dept of   430000 0 0 2017-07-17T14:08:28.857000-04:00
1989589 NATIONAL NURSES UNITED c67acff4-d2ce-44d9-9a1e-075753262e27 Q2 NATIONAL NURSES UNITED 40021153 NATIONAL NURSES UNITED 2017 second_quarter PHA H.R. 1245 - support for Affordable & Safe Prescription Drug Importation Act H.R. 1776 - support for Improving Access to Affordable Prescription Drugs Act HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2017-07-17T14:49:07.517000-04:00
1989668 MEHLMAN CONSULTING, INC. 0c5ff2c9-8a96-47b2-b1fe-652508e3ef89 Q2 MEHLMAN CONSULTING, INC. 284950 VIRTUS PHARMACEUTICALS LLC 2017 second_quarter PHA FDA Drug Approval HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2017-07-17T14:59:59.190000-04:00
1989970 NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE a92cea2a-21be-471c-bc80-72a8a9abd472 Q2 NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE 48975 NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE 2017 second_quarter PHA Support maintaining ACA Patient Protections and Access to Prescription drugs Support S. 469 / HR 1245, the Affordable and Safe Prescription Drug Importation Act Support Klobuchar Amendment #178 to S. Con. 3 which established a deficit neutral fund relating to lower drug prices for Americans by importing prescription drugs from Canada. Support Wyden amendment #188 to S Con Res 3 creating a point of order against legislation that does not lower drug prices. Agriculture, Dept of (USDA),Bureau of Alcohol Tobacco Firearms & Explosives,Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Education, Dept of,Election Assistance Commission (EAC),Environmental Protection Agency (EPA),Equal Employment Opportunity Commission (EEOC),Federal Communications Commission (FCC),Federal Housing Finance Agency (FHFA),Federal Motor Carrier Safety Administration,Federal Reserve System,Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Justice, Dept of (DOJ),Labor, Dept of (DOL),Natl Park Service (NPS),Office of Management & Budget (OMB),Office of the Comptroller of the Currency (OCC),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),State, Dept of (DOS),Transportation, Dept of (DOT),Treasury, Dept of,White House Office   70000 0 0 2017-07-17T15:55:14.230000-04:00
1989985 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 07ed27e8-7a56-4e95-9374-37487608c696 Q2 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2017 second_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   270000 0 0 2017-07-17T15:56:23.167000-04:00
1990219 POWERS PYLES SUTTER & VERVILLE, P.C. e64d13d8-434e-42c1-9604-00126f78197c Q2 POWERS PYLES SUTTER & VERVILLE, P.C. 32008 340B HEALTH 2017 second_quarter PHA Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3)finding of the Health Resources and Services Administration (HRSA) under the Labor Health & Human Services & education appropriations bills. HOUSE OF REPRESENTATIVES,SENATE 25000   0 0 2017-07-17T17:02:08.470000-04:00
1990394 ROCK & ASSOCIATES db3b05c7-3117-49ac-bcb1-12264a2c50e7 2A ROCK & ASSOCIATES 33545 PRECISION PHARMACY 2017 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2017-07-17T19:03:39.387000-04:00
1990605 DAVE KOLBE CONSULTING 37330c5e-d1dc-45ad-bab8-9b01e235e6f8 Q2 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2017 second_quarter PHA Medicare Part-D rebates Trade agreements Patent reform issues HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2017-07-18T08:49:45.667000-04:00
1990720 KING & SPALDING LLP 961401e7-5ec9-440e-8615-86611f3549ef Q2 KING & SPALDING LLP 21632 SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) 2017 second_quarter PHA Issues related to inclusion of prescription drugs within Essential Health Benefit and mental health coverage expansion HOUSE OF REPRESENTATIVES,SENATE     0 0 2017-07-18T09:51:17.800000-04:00
1990746 TRAVERE THERAPEUTICS 06dd84cb-d3f6-4b91-8875-64ffcd0e3e1a Q2 TRAVERE THERAPEUTICS 401104190 TRAVERE THERAPEUTICS 2017 second_quarter PHA Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization, FAST Generics and CREATES Acts, FDA issues HOUSE OF REPRESENTATIVES,SENATE   140000 0 0 2017-07-18T09:55:26.940000-04:00
1990779 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) d67c1753-78ec-4e3b-9154-00a8d5c361e4 Q2 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2017 second_quarter PHA Rx Pedigree (Public Law 113-54); Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Prescription Drug Abuse - General issues related to Rx drug abuse; Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   302000 0 0 2017-07-18T10:02:47.770000-04:00
1990797 THORN RUN PARTNERS feb402ef-8c59-4d96-b911-f865ae8ddac2 Q2 THORN RUN PARTNERS 400534596 EXPRESS SCRIPTS, INC. 2017 second_quarter PHA Pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. Issues related to a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Drug reimbursement and general pharmacy related issues. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; issues related to transparency of pharmacy benefit managers (PBMs). HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-07-18T10:10:00.567000-04:00
1991266 MASSACHUSETTS MEDICAL SOCIETY 9524e962-b455-4ab3-87a3-061becba9b46 Q2 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2017 second_quarter PHA S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2017-07-18T11:52:31.607000-04:00
1991270 ASCENSION HEALTH 9a636286-5008-4eff-81ad-9193a2ca20ba Q2 ASCENSION HEALTH 53301 ASCENSION HEALTH 2017 second_quarter PHA Drug pricing; Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES) FAIR Drug Pricing Act Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   248000 0 0 2017-07-18T11:53:34.453000-04:00
1991656 WINNING STRATEGIES WASHINGTON fca37d82-3d97-4fd0-9d2c-92c4260e4d01 Q2 WINNING STRATEGIES WASHINGTON 50796 KALEO 2017 second_quarter PHA Pharmaceutical drug development including epinephrine for anaphylaxis HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE 30000   0 0 2017-07-18T13:25:31.510000-04:00
1991684 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION a7667959-d663-4d46-b9ea-5152afa4cb29 Q2 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2017 second_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   215000 0 0 2017-07-18T13:28:45.493000-04:00
1991818 TARPLIN, DOWNS & YOUNG, LLC af8b7066-30ba-47ee-92a8-c7a9919e9f3d Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 ASTRAZENECA 2017 second_quarter PHA PL 114-255 - 21st Century Cures, implementation H.R. 2430 - FDA Reauthorization Act of 2017 ***, no specific bill(s), Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-07-18T13:49:12.200000-04:00
1992021 BLUECROSS BLUESHIELD OF TENNESSEE 89bddcc8-6b76-4b16-8945-25ada3bd81e6 Q2 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2017 second_quarter PHA General pharmacy and pharmaceutical issues; Opioid Abuse; prescription drug pricing Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2017-07-18T14:21:50.610000-04:00
1992114 ALKERMES, INC. a0d66aa1-63d0-4e8b-a168-d34ddd1e1de8 Q2 ALKERMES, INC. 400458235 ALKERMES, INC. 2017 second_quarter PHA Public law #114-198, Cures Opioid Funding Implementation H.R. 2430 FDA Reauthorization Act of 2017 S.934 FDA Reauthorization Act of 2017 Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Veterans Affairs, Dept of (VA)   940000 0 0 2017-07-18T14:36:56.847000-04:00
1992566 FOLEY & LARDNER LLP dfe7601c-16b4-4581-b2ff-33dc62ba7612 Q2 FOLEY & LARDNER LLP 15042 ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY 2017 second_quarter PHA FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-07-18T15:21:27.040000-04:00
1992671 AMERICAN PHARMACISTS ASSOCIATION 72dee276-628d-479d-9154-c785ed14cc83 Q2 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2017 second_quarter PHA HR 1038, S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act HR 1939 To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes. HR 592, S 109 To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services. HR 1480 Safe and Affordable Drugs from Canada Act of 2017 S 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 HR 1586 To amend the Federal Food, Drug, and Cosmetic Act to ensure that liquid over-the-counter medications are packaged with appropriate dosage delivery devices and, in the case of such medications labeled for pediatric use, appropriate flow restrictors, and for other purposes. S 778 Prescription Drug Monitoring Act of 2017 HR 934 Personal Drug Importation Fairness Act of 2017 HR 421 Allowing Greater Access to Safe and Effective Contraception Act HR 1436 To provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017. HR 1245, S 469 To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals. HR 3268 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 (drug compounding provisions) S 1079 Protecting Americans from Dangerous Opioids Act HR 2430 FDA Reauthorization Act of 2017 HR 2567 Access to Birth Control Act HR 2871 Preserving Patient Access to Compounded Medications Act of 2017 HR 2063 Opioid PACE Act of 2017 S 1003 A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes HR 1939/S 1044 Ensuring Seniors Access to Local Pharmacies Act of 2017 HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2017-07-18T15:34:41.917000-04:00
1992834 FOLEY & LARDNER LLP 4b9bccfb-b50c-4530-9879-d86b6b192fe1 Q2 FOLEY & LARDNER LLP 15042 PAR PHARMACEUTICAL 2017 second_quarter PHA FDA issues HOUSE OF REPRESENTATIVES,SENATE     0 0 2017-07-18T15:55:44.480000-04:00
1992918 CARD & ASSOCIATES, LLC bac11409-b276-42ef-a9fe-c6f7dc327de4 Q2 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2017 second_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers H.R. 1316 Prescription Drug Price Transparency Act S. 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2017-07-18T16:07:37.607000-04:00
1993193 GREATER NEW YORK HOSPITAL ASSOCIATION 891f5c91-ec63-4856-8e0d-9002d12a3f20 Q2 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2017 second_quarter PHA Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases. Support drug pricing legislation that would promote competition by fast tracking generic drug applications (H.R. 749/S.297). Oppose legislation that would harm the 340B drug discount program for safety net hospitals. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   540000 0 0 2017-07-18T16:39:13.110000-04:00
1993201 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING b0fe8814-d1cb-424e-a246-a3463fd21771 Q2 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2017 second_quarter PHA Compounding of radiopharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE   50000 0 0 2017-07-18T16:40:15.720000-04:00
1993351 ACADEMY OF MANAGED CARE PHARMACY c0feb6ac-cee5-45d0-bc59-d85bc8ba1ad2 Q2 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2017 second_quarter PHA Letters of support for the CREATES Act (H.R. 2212 and S. 974), the FAST Act (H.R. 2051) and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on biosimilars and interchangeability, Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2017-07-18T17:08:57.550000-04:00
1993366 TARPLIN, DOWNS & YOUNG, LLC 9bbad209-3533-4955-bffc-b136bfcc8721 Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 PHRMA 2017 second_quarter PHA PL 114-255 - 21st Century Cures, implementation H.R. 1628 - American Health Care Act of 2017 ***, no specific bill(s), prescription drug importation, import safety, supply chain integrity, Prescription Drug User Fee Act Fee Reauthorization and associated policies, user fee sequester, innovation Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2017-07-18T17:13:04.803000-04:00
1993398 PRIME THERAPEUTICS 1f58811f-1516-40e0-91d8-e8049aa3de50 Q2 PRIME THERAPEUTICS 400339576 PRIME THERAPEUTICS 2017 second_quarter PHA H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act --issues relating to noninterference and workability. S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. S.1003: To amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes; provisions related do drug coverage in Medicare and Medicaid. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2017-07-18T17:24:28.943000-04:00
1993426 THE INGRAM GROUP LLC 285785fa-2a22-4c14-8566-d39c971e118d Q2 THE INGRAM GROUP LLC 400577737 ELI LILLY AND COMPANY 2017 second_quarter PHA General issues related to the biopharmaceutical and pharmaceutical industries including drug importation. H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-07-18T17:32:50.617000-04:00
1993445 APOTEX CORP. b90e200b-d219-4003-896a-b4a08e5d399e Q2 APOTEX CORP. 310973 APOTEX CORP. 2017 second_quarter PHA HR 2430, the FDA Reauthorization Act of 2017, Title VIII, Improving Generic Drug Access, provisions relating to enhancing the generic drug approval process, spurring the development and approval of generic versions of drugs with limited competition, and generic drug exclusivity; S. 934, the FDA Reauthorization Act of 2017, Title IX, Generic Drug Access, provisions relating to enhancing the generic drug approval process and spurring the development and approval of generic versions of drugs with limited competition; HR 2212, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; S. 974, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; HR 2051, the Fair Access for Safe and Timely Generic Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; and Federal policy related to repealing Section 603, Applying the Medicaid additional rebate requirement to generics, of Public Law No 114-67, the Bipartisan Budget Act of 2015 HOUSE OF REPRESENTATIVES,SENATE   300000 0 0 2017-07-18T17:40:11.930000-04:00
1993454 KOUNTOUPES DENHAM CARR & REID, LLC 097532e5-4a24-4429-ba9a-fb1e7bfe6d3a Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2017 second_quarter PHA General issues related to over the counter pharmaceuticals, cosmetics issues related to Rx/OTC transition issues related to draft legislation addressing the over the counter drug monograph process, and H. R. 2430, the FDA Reauthorization Act (FDARA) of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-07-18T17:42:18.900000-04:00
1993683 THORSEN FRENCH ADVOCACY LLC 611ad2ac-40b8-4c3a-895d-37ba60d40382 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 CARDINAL HEALTH, INC. 2017 second_quarter PHA Issues related to prescription drug abuse. Issues related to pharmaceutical market value. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-07-18T20:40:59.220000-04:00
1993700 THORSEN FRENCH ADVOCACY LLC 955aa0d7-bd72-43c8-a5e5-451b4c00499f Q2 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2017 second_quarter PHA General issues related to prescription drug abuse. Issues related to pharmaceutical market value. Prescription drug importation. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-07-18T20:54:12.327000-04:00
1993710 THORSEN FRENCH ADVOCACY LLC 96d07d94-e754-4d6b-93aa-d55d04f963ff Q2 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2017 second_quarter PHA Issues related to pharmaceutical market value. Issues related to prescription drug abuse. H.R.2212: CREATES Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2017-07-18T21:01:22.767000-04:00
1993835 DAIICHI SANKYO, INC. cf66dd7b-4193-4c3b-aad9-e8ec94cfa540 Q2 DAIICHI SANKYO, INC. 316731 DAIICHI SANKYO INC 2017 second_quarter PHA H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 H.R.2430 and S.934, FDA Reauthorization Act of 2017 HOUSE OF REPRESENTATIVES   150000 0 0 2017-07-18T23:39:05.707000-04:00
1994385 ANIMAL HEALTH INSTITUTE 8667f447-e336-400c-b408-f3efe7bc0eef Q2 ANIMAL HEALTH INSTITUTE 4037 ANIMAL HEALTH INSTITUTE 2017 second_quarter PHA Issues related to illegal drug manufacturing under the guise of pharmacy compounding; Issues related to the granting of Categorical Exclusions for animal health products. Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)   35000 0 0 2017-07-19T09:45:19.420000-04:00
1994566 TRAVERE THERAPEUTICS 030a4f97-e7a9-4db6-9177-e55b11420a48 2A TRAVERE THERAPEUTICS 401104190 TRAVERE THERAPEUTICS 2017 second_quarter PHA Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization, FAST Generics and CREATES Acts, FDA issues HOUSE OF REPRESENTATIVES,SENATE   170000 0 0 2017-07-19T10:19:20.580000-04:00
1994921 BUCHANAN INGERSOLL & ROONEY PC dc95950d-8027-43bc-9ddf-b917ef1e2801 Q2 BUCHANAN INGERSOLL & ROONEY PC 55291 WOMEN'S CHOICE PHARMACEUTICALS, LLC 2017 second_quarter PHA Development of government relations strategy relating to prenatal dietary supplements. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2017-07-19T11:00:03.663000-04:00
1994925 AVENUE SOLUTIONS b1f5e704-50cd-4740-901e-a3d798fb6de1 Q2 AVENUE SOLUTIONS 72111 JAZZ PHARMACEUTICALS, INC. 2017 second_quarter PHA S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2017 (CREATES Act of 2017); H.R. 2051, FAST Generics Act HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-07-19T11:01:06.270000-04:00
1995124 UNIVERSITY OF IOWA b5860689-908c-40d3-85eb-941e77cd48c8 Q2 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2017 second_quarter PHA FY 17 and FY 18 appropriations for NIH Support for palliative care programs Support for 340B program Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT)   86662 0 0 2017-07-19T11:19:05.057000-04:00
1995302 FTI GOVERNMENT AFFAIRS 2de028ac-bd06-4984-89c3-c46acdbd25a9 Q2 FTI GOVERNMENT AFFAIRS 401054971 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2017 second_quarter PHA Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R.2871 "Preserving Patient Access to Compounded Medication Act of 2017. " HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2017-07-19T11:33:56.120000-04:00
1995338 SC PARTNERS LLC 5860dfdd-0550-458b-9e62-04c9f9a2cf45 Q2 SC PARTNERS LLC 318994 PFIZER, INC. 2017 second_quarter PHA Advocated for maintaining a safe prescription drug supply, and shared concerns about the safety and economic implications of allowing the importation of prescription drugs and biologics from Canada and other countries. Affordable and Safe Prescription Drug Importation Act (S. 469) HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2017-07-19T11:36:26.087000-04:00
1995445 TARPLIN, DOWNS & YOUNG, LLC 8e4ec86f-5955-4484-87cc-f57ea25b290c Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 BIOTECHNOLOGY INDUSTRY ORGANIZATION 2017 second_quarter PHA PL 114-255 - 21st Century Cures, implementation H.R. 2430 - FDA Reauthorization Act of 2017 ***, no specific bill(s), Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 80000   0 0 2017-07-19T11:46:43.857000-04:00
1995670 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) d74eca28-9b5a-436d-a4ac-b621f9e437fb Q2 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 400265214 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 2017 second_quarter PHA Pricing, shortages, and safety issues Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   137625 0 0 2017-07-19T12:14:16-04:00
1995725 FORGE FEDERAL AFFAIRS LLC 91b075d2-d59d-4f83-ab2a-9599cdebf2c8 Q2 FORGE FEDERAL AFFAIRS LLC 400865535 LILLY USA LLC 2017 second_quarter PHA Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to reauthorization of the Prescription Drug User Fee Act. H.R.2430/S.934, FDA Reauthorization Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2017-07-19T12:19:53.483000-04:00
1995868 AMERICAN ASSOCIATION FOR JUSTICE 29b88846-1f22-450d-96a4-bc0671976bef Q2 AMERICAN ASSOCIATION FOR JUSTICE 4733 AMERICAN ASSOCIATION FOR JUSTICE 2017 second_quarter PHA S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law. S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors. S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids. S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances. General Lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to off label promotion of pharmaceutical products. General lobbying with regard to pharmaceutical drug advertising. General lobbying with regard to pharmaceutical price-gouging. Lobbying with regard to biosimilar naming and labeling. Lobbying with regard to updating generic drug labeling responsibilities. Consumer Financial Protection Bureau (CFPB),HOUSE OF REPRESENTATIVES,SENATE   1940000 0 0 2017-07-19T12:36:24.143000-04:00
1996113 MERCURY PUBLIC AFFAIRS, LLC 582b708e-eb7c-4f45-9855-6ab929cafb31 Q2 MERCURY PUBLIC AFFAIRS, LLC 70175 KALISPELL REGIONAL HEALTHCARE 2017 second_quarter PHA Veteran pharmacy issues and polices Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2017-07-19T13:15:02.663000-04:00
1996301 BUCHANAN INGERSOLL & ROONEY PC 6c606795-50f4-4ab0-9395-23ec8e4365a4 Q2 BUCHANAN INGERSOLL & ROONEY PC 55291 TONIX PHARMACEUTICALS HOLDING CORP. 2017 second_quarter PHA Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2017-07-19T13:30:43.243000-04:00
1996492 TARPLIN, DOWNS & YOUNG, LLC 4cd9c9d2-c6f6-4286-b5ea-56a089243e18 Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2017 second_quarter PHA Importation of prescription drugs (S. 469, S. 771, H.R. 1776, H.R. 1245, H.R. 934, H.R. 1480, S. 92, S. 64) Rx Pedigree (PL 113-54) Prescription Drug Monitoring Programs (S. 480, H.R. 1725) Prescription Drug Abuse - General issues related to Rx drug abuse Ensuring Patient Access and Effective Enforcement Act (PL 114-145) Implementation of Public Law 113-54 (DSCSA) Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2017-07-19T13:46:40.697000-04:00
1996606 ELI LILLY AND COMPANY 5bbd7163-7bea-43db-8ec9-befede69e9d0 Q2 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2017 second_quarter PHA Hospital discounts; 340B program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   2020000 0 0 2017-07-19T13:52:38.417000-04:00
1996981 OREGON HEALTH & SCIENCE UNIVERSITY cdf58f4d-4226-4a04-8106-dd799a90c9d9 Q2 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2017 second_quarter PHA 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2017-07-19T14:18:07.810000-04:00
1997180 BLUE CROSS AND BLUE SHIELD ASSOCIATION fb352986-5f32-4e7d-b839-dae15aabe954 Q2 BLUE CROSS AND BLUE SHIELD ASSOCIATION 6358 BLUE CROSS AND BLUE SHIELD ASSOCIATION 2017 second_quarter PHA Opioid Abuse; Drug Pricing; HR 2026 Pharmaceutical Information Exchange Act Introduced April 6, 2017 by Brett Guthrie (R-VA) To improve patient access to emerging medication therapies by clarifying the scope of permitted health care economic and scientific information communications between biopharmaceutical manufacturers and population health decision makers. HR 2051 FAST Generics Act Introduced April 6, 2017 by David McKinley (R-WV) To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products,so as to enable eligible product developers to develop and test new products, and for other purposes. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Treasury, Dept of,Vice President of the U.S.,White House Office   2050000 0 0 2017-07-19T14:29:41.343000-04:00
1997391 AVENUE SOLUTIONS 98a5e82d-c709-4551-a8b3-7c92f9ac2280 Q2 AVENUE SOLUTIONS 72111 MOMENTA PHARMACEUTICALS, INC. 2017 second_quarter PHA Improving access to biogenerics HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2017-07-19T14:51:18.890000-04:00
1997477 POLITICAL CAPITAL, LLC 8fbd6145-9eb3-45b2-9afb-98ea2514df95 Q2 POLITICAL CAPITAL, LLC 401104260 MEDISCA INC 2017 second_quarter PHA DQSA Oversight HR 2871 Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2017-07-19T14:56:13.337000-04:00
1997487 AVENUE SOLUTIONS 5b715d12-485d-415a-9e67-fc942ffa8e5f Q2 AVENUE SOLUTIONS 72111 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 2017 second_quarter PHA Issues related to biosimilars SENATE 80000   0 0 2017-07-19T14:57:19.853000-04:00
1997655 ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) 5cdc3531-6963-45e6-a0d5-e3c5a3f8c876 Q2 ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) 400637926 ACCREDITATION COMMISSION FOR HEALTH CARE 2017 second_quarter PHA Legislation & regulations impacting Pharmacy Compounding. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 5000   0 0 2017-07-19T15:08:13.683000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2103.872ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API